Old and New Blood Markers in Human Colorectal Cancer

Area of Science:

• Oncology
• Biomarker Discovery
• Cancer Diagnostics

Background:

• Cancer remains a leading global cause of mortality, with significant incidence in both men and women.
• Despite advancements, improving cancer detection and prognosis assessment remains a critical challenge.
• Current diagnostic and prognostic tools, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), lack definitive utility.

Purpose of the Study:

• To explore novel biomarkers for cancer detection and prognosis.
• To evaluate the potential of specific molecules like CD66 and cytokines in assessing disease severity.
• To investigate the role of circulating tumor DNA (ctDNA) in managing specific cancer types.

Main Methods:

• Review of existing literature on cancer biomarkers and detection methods.
• Analysis of the role of carcinoembryonic antigen cell adhesion molecule (CEACAM) family, including CD66.
• Examination of cytokine profiles (IL-6, IL-17A, IL-22, TGF-β) in tumor tissues.
• Assessment of circulating tumor cell (CTC) detection and circulating tumor DNA (ctDNA) studies.

Main Results:

• The CEACAM family, particularly CD66, shows potential as an indicator of disease severity.
• Elevated levels of interleukin-6 (IL-6) correlate with higher patient mortality rates.
• Other cytokines like IL-17A, IL-22, and TGF-β are expressed at the tumor level.
• Circulating tumor DNA (ctDNA) shows promise for chemotherapy management in Stage II colorectal cancer (CRC) patients.

Conclusions:

• Novel biomarkers beyond traditional markers are needed for improved cancer management.
• CD66 and ctDNA represent promising avenues for enhancing cancer prognosis and treatment strategies.
• Further research into cytokines and cell adhesion molecules could yield significant advancements in oncology.